Abatacept in combination with post-transplant cyclophosphamide and tacrolimus may improve survival and non-relapse mortality without increasing relapse risk after allogeneic stem cell transplantation
Retrospective study found abatacept improves overall survival in patients with hematological malignancies, suggesting benefits for graft versus host disease prevention.
Key Points
This research aims to compare the outcomes of abatacept in combination with PTCy and TAC versus conventional therapy in stem cell transplantation.
Retrospective review of 99 patients receiving allogeneic HCT with PTCy-based GVHD prophylaxis from 2021 to 2025.
Comparison between two groups: TAC/ABA/PTCy and TAC/MMF/PTCy.
Outcomes assessed included survival rates, GVHD incidence, and patient demographics.
Overall survival at 1 year was 84.8% for TAP group compared to 69.7% for TMP group (P=0.019).
TAP group had lower risk of acute GVHD (33.3%) compared to TMP group (51.5%, P=0.04).
Cumulative incidence of chronic GVHD was higher in TAP group (66.2%) versus TMP group (39.4%) at 1 year (P=0.07).